Cogent Biosciences, Inc Investor Event Transcript, Nov 17, 2026
Cogent Biosciences, Inc. (COGT)
Cogent's lead drug bezuclacinib has PDUFA dates of November 30 for imatinib-resistant GIST, December 30 for non-advanced systemic mastocytosis, and June 29, 2027 for advanced systemic mastocytosis. The company says it is ready to ship product within two or three days of approval. AI summary
Conference Transcript - COGT 2026-11-17
Michael Yee, Other
Thank you, everyone, for joining us on our next session. I'm Michael Yee, Global Head of Biotech Research here at UBS, and very pleased to have Cogent Biosciences here with us. And up here on the stage is Andrew Robbins, the President and CEO of Cogent. Thank you very much for being here. It's a pleasure to see you.
Andrew Robbins, CEO
Well, thanks for inviting us. We're happy to be here. It looks like the rain's stopping, so it's nice to be in London. Thanks for having us. Perfect.
Michael Yee, Other
Well, it is exciting times for Cogent because Cogent is on the brink of two or three, actually, potential FDA approvals, and two of them coming potentially in the next couple of months. If we could just maybe start from a high-level perspective, can you talk about where Cogent is with your drug and specifically where you are in the regulatory filings for which indications? And then maybe we can go into some of each of those.
Andrew Robbins, CEO
Sure. We're happy to do that. So very briefly, for those that aren't familiar, Cogent is a company that's focused on creating small molecule kinase inhibitors for patients with rare genetically driven diseases. Our lead asset is a drug known as bezuclacinib, which is a selective and potent kit mutant inhibitor that's under development for three distinct patient populations. Two forms of a disease called systemic mastocytosis, both the advanced form and the non-advanced form, as well as imatinib-resistant gastrointestinal stromal tumor patients. For each of those indications, we completed a pivotal study. Interestingly, all three of those pivotal studies had their positive results readout in 2025. So, 2026 really was always meant to be a year of regulatory submissions and working with the FDA specifically to try to bring this medicine to these three distinct patient populations. To Mike's specific question, we have formal PDUFA dates announced, and they remain in place for all three with a November 30th, which is literally days away for our first, hopefully, approval in second-line GIST or imatinib-resistant GIST patients. Then on December 30th, a PDUFA date for the non-advanced systemic mastocytosis indication, which was from a trial called the SUMMIT trial. And then finally, for the advanced form of mastocytosis, which is June 29th of 2027, and that is based on the positive results from what's known as the APEX study. I'm sure we can talk a little bit about each of those.
Michael Yee, Other
Fantastic. Well, you have three filings going on at the FDA, so you're keeping the FDA busy. So on November 30th, there's a Pidufa date. Let's kind of go through these chronologically. I think these are all huge opportunities. This is multi-billion. We'll talk about these opportunities each. But first, we've got to get approvals. And so in second-line gist, which could be a couple billion dollars, unmet need. Very strong phase three results. You have an FDA approval. Now, can you just talk about what your expectation is for approval? Do we expect a very clean label? Would there be any black box on this? Because investors say your drug is on top of Sutent versus Sutent alone. Fantastic data, but Sutent has a black box. So how does that work? Does your drug get a black box on that, or does it get a black box?
Andrew Robbins, CEO
Right. We're obviously very aware of this narrative. What I can tell you is a few things. Number one, we, in our opinion, have very carefully characterized the behavior of bezuclacinib. Bezuclacinib does really one thing exceptionally well, and that targets and kills cells that have KIT mutations in them. From a tolerability perspective, across all of our studies in a patient database, which is now well above 1,000 people who have taken our drug, it's a very consistent safety profile, and it really does three things. At a low level, sometimes patients report that they have salty taste changes. Patients sometimes demonstrate white hair growth, which is an on-target effect of hitting kit. And then the one that people talk about the most is a tyrosine kinase inhibitor, which is a pretty common adverse event for tyrosine kinase inhibitors. We have demonstrated that the drug can cause fluctuations in transaminases. What's important, though, is across all these studies at all the various doses, we don't have a signature of the drug causing clinical sequelae as a result of the transaminase fluctuation. So in almost all patients, without any dose modifications, we can give the bezuclacinib chronically to people. In a smaller number of patients with a dose reduction, those patients can resolve to baseline levels and take the drug chronically. And only in very, very rare cases have we had to withhold the drug from someone or discontinue the drug. In every one of those cases, the patient's transaminase levels went back to baseline with no clinical sequelae.
Michael Yee, Other
If a patient has second-line gist cancer, I don't think people are concerned about white hair or salty taste.
Andrew Robbins, CEO
I agree with that.
Michael Yee, Other
So, given ALT is a common concern, and certainly not a concern for cancer, I don't think this is a concern. The idea was that I would love to offer you the opportunity, and certainly I've been saying, but I'd like to understand why would a black box matter in gist, and I appreciate that if there was one, wouldn't it just be cut and paste from the same suitant label?
Andrew Robbins, CEO
Well, that's the excellent point, is because for folks who have an idea or an uncertainty about the impact of a black box for transaminases in this patient population, The best use case is the fact that the standard of care for the past 20 years has a black box for this exact same issue. So it has not dissuaded the entire world from adopting sunitinib as the standard of care in these patients. And if you were to hypothesize that there were going to be a physician and patient conversation about a drug with a warning or monitoring for transaminases, if you decided not to do that, your fallback would be a drug that has it already. So we see that there is absolutely no change to the workflow for giving patients a drug bezuclacinib in combination with sunitinib to noticeably change the clinical outcomes as measured on PFS and ORR and even as PFS2 as a proxy for survival. We think that this launch will be very successful and very rapid, especially in the U.S., where cancer medicines that have demonstrated things like hazard ratios of around 0.5, in a market where nothing has been approved for 20 years, I think it's going to go very well.
Michael Yee, Other
So, again, I don't understand this narrative, but if a black box occurred, that would mostly be because of the Sutent indication. We were able to find one drug that is used in combination with another drug, and that other drug in combination does have a black box, and that was the antibody drug conjugate from Pfizer-CGEN to Kiza. In that case, it just references it. But any time you have a drug and it's used in combination, it may reference that black box because of that.
Andrew Robbins, CEO
I think it's hard sometimes to take historical FDA behavior and use it today to predict future FDA behavior. So everything you just said makes sense to me, but I can't prove that it is 100% certain.
Michael Yee, Other
My point is that black box doesn't matter if you're in second-line gist.
Andrew Robbins, CEO
I agree. To me, there is no question commercially, it will not have any noticeable effect on the commercial uptake of bezuclacinib in gist patients.
Michael Yee, Other
Maybe it's because of a read-through to ISM, which we'll get to in a second, but again, in oncology, it doesn't matter because it's used on top of the drug, which has a black box. Liver monitoring, though, that would be expected. Again, no change to the workflow, but liver monitoring is because of the ALT, and that doesn't matter either because they're already getting liver monitoring for Sutent. Liver monitoring generally would be expected.
Andrew Robbins, CEO
Correct. I think we would agree with that. I think it is a good idea, given the profile of the drug, especially early in the treatment course, to monitor patients on a regular basis. But what we've seen is any of the higher-grade transaminase elevations have occurred very early in initiation of treatment. So I don't know that long-term it's going to be required, but we stipulate and we agree that it is a good idea early in treatment for anybody starting BESU class.
Michael Yee, Other
What would be a base case or what is a reasonable time for monitoring? I'm not exactly sure how FDA looks at that. Maybe it's based on the onset of when the ALTs occurred, but, like, is three months, six months, monthly? How do you think about that?
Andrew Robbins, CEO
The current label for sunitinib as a good proxy is monthly monitoring. I think it is not defined. I think it's monthly monitoring and as clinically indicated.
Michael Yee, Other
Got it. So again, these are all standard as it relates to the label for Sutent. And just as we finish off on gist, how do you think about the market opportunity for this? And secondly, we recently found that GSK has now started a phase three for their own version of a wild type kit, but it's a very different type of trial design. And GSK recently made some comments about this, how they prefer monotherapy versus Sutent. But, Jed, let's quantify the market opportunity.
Andrew Robbins, CEO
Sure. So the market that we're preparing to launch into, which is imatinib-resistant, we estimate there to be between 2,500 and 3,000 patients a year who develop resistance to imatinib and become eligible for our combination therapy once approved. Based on the mean duration of treatment that we demonstrated in the peak phase 3 trial of the last time we checked, this was 21.4 months. It's a very robust average duration of treatment. When you model this out, we think over several years, we will turn many of these patients from an incidence disease into a prevalence disease so that you don't just take into account how many patients each year develop resistance. You have to take into account for how many years will patients take the combination. So our modeling suggests this is about a $2.5 billion opportunity in the U.S. with the potential as a very effective therapy for a rare cancer indication to also be commercially relevant in other territories like Europe and Japan and the rest of the world.
Michael Yee, Other
What is the $2.5 billion market based on what pricing and what price? I know Kinloch, which is a drug we're familiar with, is about $400,000, although it's fourth line. Does the price get more expensive or cheaper as you move upstream? How are current rare disease oncology drugs priced?
Andrew Robbins, CEO
Yep. In general, I think you're seeing rare cancer drugs launching with prices in the high $40,000, almost $50,000 per month wholesale acquisition cost range, Which, to your point, the proxy in just Kinloch or Repretinib is in that neighborhood. I think they're at $47,000 and change. Conveniently for us, on the other indication, which we're about to talk about in mastocytosis, probably the most natural proxy is a drug called Avakit. And Avakit is also a very high-priced oral therapeutic. It's priced at a little over $44,000 a month wholesale acquisition cost. Very similar, which for us is nice. We're not going to have to probably spend a lot of time with payers justifying a significant premium to the available therapies. I think the available therapies have already set a very good benchmark.
Michael Yee, Other
RevMed was also a recently approved drug, and they're in the same price range. Okay, so there's your pricing. Now, as we get to December, there's a second indication, And this is quite interesting because the market is pretty familiar with AvaKit from Blueprint. I covered Blueprint. The company was sold for about $9 billion to Sanofi. Sanofi thinks this could be a couple billion dollar indication just in ISM. So if you just spoke about GIST in $2.5 billion, and right the next month later, you have an indication that Sanofi Blueprint, I think, is also $2 to $3 billion. I mean, technically, this is like a $5 billion between the two of them. How does your drug compare to AvaKit profile for ISM, and how should we think about this when it comes to December?
Andrew Robbins, CEO
Yeah, it's an excellent question. So both of our drugs, if you look at them non-clinically, are nearly identical on their potency against the main driver mutation of mastocytosis, which is known as D816V. It's a point mutation in kit exon 17. The key differences between our drugs is Avakit is not a selective kit inhibitor. It also inhibits PDGFR, as evidenced by the fact that it's approved by the FDA for a PDGFR disease, as well as it has some activity on CSF1R and FLT3. So it is a pan-kinase inhibitor. And also, Avakit is one of the most CNS-penetrant drugs for any target for any disease, where they're actually preferential to CNS tissue over systemic delivery of the drug.
Michael Yee, Other
That's why they have CNS talks.
Andrew Robbins, CEO
They have CNS talks. And so the consequence of that is, well, the clinically relevant dose of Avakit in their first couple of approvals was between 200 and 300 milligrams. In order to move forward and get their drug approved for the non-advanced patient population, which is a disease of morbidity, not mortality, they had to reduce their dose to 25 milligrams. So they sacrificed a significant proportion of the therapeutic index to spare the CNS toxicity that they saw at those higher doses. Our drug is non-CNS penetrant and highly selective for kit, and that allows us, even in the non-advanced population, to dose to the clinically relevant level, and we have demonstrated on PD measures, on molecular measures, a noticeable advantage on clearance of things like serum tryptase, mast cell burden, varying allele frequency, and that is where I see the future of treatment in non-advanced going. is not a disease of how can I make a patient feel better. It's really to use a drug like bezuclacinib to try to remove the clonal mutant cells altogether from the patient and drive towards a complete remission.
Michael Yee, Other
So comparable profile, in terms of comparing the profile, do you believe that your drug also has higher efficacy and a better safety tolerability profile as to those You've already been looking at AvaKit and invest in Sanofi?
Andrew Robbins, CEO
I think it's very hard to argue against AvaKit's safety profile by reducing their dose by 90%. They're a very well-tolerated drug, but they are not a very effective drug at that dose, which is evidenced by their, I think, quiet, continued push to use their drug at higher doses because the 25-milligram dose just does not get the job done for these patients. Yes, so doctors are telling them to bump up the dose. Bump up the dose. And what we don't know is in between their labeled dose for non-advance and their labeled dose for some of the other diseases where they have shown evidence of intracranial hemorrhage and significant cognitive impairment, where is the break point? So as you move the dose up with that drug, you are starting to take the risk in those patients of some of those off-target side effects, where we have seen none of those classical signatures of intracranial hemorrhage and cognitive impairment on our profile at any dose.
Michael Yee, Other
And so from an efficacy perspective, since you didn't have to dial back, although the two endpoints are slightly different, in general, I feel like your efficacy is about 15% to 20% better when comparing cross-trial endpoints.
Andrew Robbins, CEO
So there's a couple ways to think about efficacy in this patient population. The classical regulatory endpoint is a total symptom score. So it's measuring how do patients feel on a questionnaire that they fill out. And we acknowledge that because Blueprint trademarked theirs, we couldn't use it. We had to create our own version of it. Trademarked their endpoint. They trademarked their endpoint. So we can talk about symptoms. We can also talk about objective measures of disease, which are not trademarked. And you can really do a nice job comparing. On symptomatic improvement, we acknowledge, again, that these are different scales. We do continue to show symptomatic improvement post six months, where if you look at the long-term benefit of AvaKit, between six months and three years, they really have no incremental noticeable symptomatic improvement. So you're taking a drug, as Mike, you mentioned, for $400,000 plus a year, and for two and a half years, you're seeing no incremental benefit. That's a tough pill to swallow, so to speak. If you look at the objective measures, that's really where our drug shines. So when you measure things like the noticeable detection of mutant mast cells in the bone marrow, which is a clear marker of this disease, in nearly two-thirds of our patients at six months, it's undetectable. To the point where the world's leading pathologist would say that that patient is no longer diagnosed with this disease. That is amazing. When you talk to KOLs about how frequently they've seen that happen with AvaKit, they say they've never seen it happen in any patient. So I think right now, based on the FDA's interest in a symptomatic primary endpoint, a lot of the comparisons are being done on symptoms. I think as we hopefully get approval and then launch the drug, we're going to try to change that conversation to which drug actually is getting rid of the underlying cells that are causing the disease, not just how do you feel.
Michael Yee, Other
Right. It's more than just symptomatic. So when this indication comes, hopefully by December 30th.
Andrew Robbins, CEO
Correct.
Michael Yee, Other
The company has a very different indication in a rare autoimmune disease versus a cancer indication. Now, the pricing philosophically could be the same, but one is for an autoimmune disease, one is for oncology. An autoimmune patient may not want to read a label that has all these black box issues and all these side effects because the combination arm basically shows all the sutent side effects. So if I have ISM, I don't want to read all of the stuff that has all these side effects like hand and foot disease and all these other things. Now, did you file for a second indication with a different trademark name, a different label, a different NDC code? Don't you want two different labels?
Andrew Robbins, CEO
So in order to make that decision, you make that decision when you submit your new drug application, not at the end. So we made that decision long ago. When we hear on the first approval, we will make that very clear, and hopefully it's not too long in the future. But what I can tell you about the dynamics of the commercial launch and non-advanced is we need to think about this a little bit more carefully. The number of brand-new diagnosed non-advanced mastocytosis patients is going to be a fraction on a monthly or quarterly basis starting in 2027 of the number of patients who have been diagnosed and who are either currently taking Ava, used to take Ava, but don't take it anymore for some problem, or are afraid of taking Avapritinib. So our commercial focus, and where we're really going to spend our time, is not trying to go head-to-head against a new patient coming in and trying to decide between two drugs. It's really going to be telling patients you deserve to try something that is going to change fundamentally the cells inside your body, not just make you feel better. And one of the ways we're going to do that is from a clinical trial that we haven't even shown the results of yet. So speaking to a couple of these different points, we ran a subsequent study called the SUMMIT sub-study, or people now refer to it as the SWITCH study, where we found patients who were taking avapritinib, either the approved dose or dose level one above the approved dose, 25 or 50 milligrams, and we measured them on our PRO to try to remove some of the specter of different PROs. So we measured them on RPRO, and we did a quick washout, and we gave them beziclacinib. And for the first time in just a few weeks at ASH, you're going to see data from that study. Now, that is going to be very illustrative for the few thousand patients who are either on AVA or used to take AVA in the U.S. to say, is there any net benefit of switching to a new drug for how you feel? Now, in my opinion, any numerical advantage is going to be compelling because if you start as a patient on a scale of 1 to 10 with a 9 out of 10 on how bad you feel, and you take avipritinib and you get to a 7 out of 10, the value proposition is do you want to stay at a 7 out of 10 for the rest of your life on how much it's impacting your life, or do you want to try something else and try to get to a 5 or a 4 or a 1 out of 10? And I think what we're going to show is bezuclastin will offer these patients that type of opportunity.
Michael Yee, Other
That is a compelling switch opportunity. I look forward to that data. If I was selling Avakit, I'd be worried about how to think about people who could start swapping off my drug. But what does that have to do with the label? So your point is, like, it doesn't matter if there's a second brand name. It doesn't matter because, you know, they're not going to read the cancer label. You want a second label, but it's not clear that that can happen because the FDA is like it does. I don't know. I don't know how it works.
Andrew Robbins, CEO
I think that this label narrative is maybe a misinformed concern about blood monitoring and the idea that patients with non-advanced mastocytosis are going to be unwilling to have blood drawn to measure something. Right.
Michael Yee, Other
So it's not even about the different brand names or the different label. It's the fact that there would be, like, liver monitoring. I don't even care about black box. The black box is not relative in gist. Again, we just talked about a SUTEN. If you have ISM and you see that there's a black box, but it's related to SUTEN, I'm sure a doctor can explain all this and all the side effects that are related to the cancer. But in ISM, there's no doubt that it's a plausible base case that liver monitoring and a monthly blood draw to monitor for that would be different than Avacit, which does not require monitoring. And your point is not a big deal.
Andrew Robbins, CEO
Well, the reason I don't think it's a big deal is I agree with your statement that their label doesn't require, but interestingly, I think there's a couple of things here that are important. The physician type that treats these patients with tyrosine kinase inhibitors is traditionally in the majority hematologists. There are also allergists, especially complex allergists or academic allergists, people who practice in an academic hospital who commonly treat non-advanced mastocytosis patients with kinase inhibitors, but the old narrative of this is a disease that is going to migrate to dermatology or primary care, it just is not believable for these patients. In order to get diagnosed, these patients typically have seven to eight physician referrals over a period of several years before they finally get to someone who can do a bone marrow biopsy, which is the way that you can confirm a diagnosis of this disease. Now that you've heard that, I think it's unsurprising that dermatologists do not do bone marrow biopsies. In order to find a physician that does this, you typically are referred to a hematologist. Now, think about a hematologist who does a bone marrow biopsy on a patient for this rare disease, and it comes back positive. The idea that they would then send them back to some other physician to get treatment is not how the practice of medicine goes. In the United States, hematologists are responsible for the vast majority of the prescriptions, and the idea that a hematologist would not want to monitor blood, it doesn't make sense to us, it does not make sense to the hematologist. That is common practice to the point where their continuing medical education that hematologists created for Avakid is frequent, indefinite blood monitoring.
Michael Yee, Other
So it doesn't matter because these are being seen by a hematologist, not an allergist.
Andrew Robbins, CEO
We think that the workflow for these patients in a commercial setting is going to be nearly identical. When you measure a patient for blood who's getting Avakit, you're probably looking first at platelet levels because it does have a history at higher doses of causing thrombocytopenia, but you're also looking for efficacy. You're looking to see what does a patient's triptase look like. The idea that, as a hematologist, you would give a patient a bottle of pills and not check to see if the pills were doing what you wanted them to do, it doesn't make sense to us. It doesn't make sense to the hematologist. So when you test somebody on bezuclacinib, your eye probably first goes to transaminases, but you're also going to look for triptase. For both of these drugs, you're looking at a little bit of side effects, but you're looking primarily to see if the drug is doing what you're intending it to do.
Michael Yee, Other
Two points on that. So when assuming we get a approval by December 30, and we start thinking about the launch, I'd like to think a little bit longer than the next month here. When we get the launch, you said that there's a compelling opportunity to get people who are unsatisfied on AvaKit, or people who have tried it and have moved off. Um, and so that's one opportunity, but as I understand it, since AvaKit's only been on the market for a couple of years, the growth of AvaKit is also them trying to go out and go find new patients. And this is one of the debates. If you followed blueprint, we got to go build that market. So they're in some cases, they're doing the work there too. You're going to be doing the work. And so they would be looking at the two side by side and say, which one I want to take that one or this one. And the idea of liver monitoring won't matter because the person who's doing all of this is a hematologist, and that's not a concern.
Andrew Robbins, CEO
I think your question is, for a brand-new diagnosed patient with a more complicated label, with monitoring, how would you predict that that's going to go? I think about it in two ways. Number one, for the individual physician we're talking about, maybe not in January of 2027, but over time, they will get experience using our drug, and when we've worked with people who have treated several patients with our drug, The response is uniformly positive. We really haven't found physicians who use bezuclacinib and don't like it. So I think the experience of the physician will be used to apply that to future patients. And then number two, a lot of what we're going to focus on in this disease setting is communicating to patients and using patients and their experience with bezuclacinib transposed with Avakitten to communicate to themselves within their community. And I think that's going to be very effective in a small rare disease population who are really looking at some other option to get further on disease control than they have with avipritinib.
Michael Yee, Other
Okay. All of this is coming in the next couple months in terms of the approval and then the launch. Are you launch ready? Are you have your field force and ready to go? You know, we are in the most significant pharma M&A environment ever, and so I would think that there's a lot of business development and strategic interest in your wholly owned global asset in a $5 billion market. But are you ready to launch a loan?
Andrew Robbins, CEO
We're absolutely ready to launch. We've added about 100 new employees to create the commercial team at Cogen, including several dozen who are spread around the country and are territory They all come from backgrounds of either or both of cancer or rare disease, so we have an exceptional team of folks assembled. From a launch readiness perspective, I think we'll be able to ship product to the first customer within two days, two or three days of approval. We need to move a few bottles around on some trucks that needs the approval to take place, but we are literally hours from fulfilling.
Michael Yee, Other
Well, it's the holidays, so for some indications, we're going to know when starting drugs, but if
Andrew Robbins, CEO
you have a second line gist, I think there's, that's true.
Michael Yee, Other
But if you've got a second line gist, you're ready to go.
Andrew Robbins, CEO
We're ready to go.
Michael Yee, Other
Thank you very much. Andrew, great to catch up with you and looking forward to these milestones. Thanks, Mike.
Andrew Robbins, CEO
Appreciate it.